A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases

Clinical trial NCT06970639 · RECRUITING

Trial details

NCT number: NCT06970639
Sponsor: Allist Pharmaceuticals, Inc.
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

NSCLC Patients With Brain Metastasis

Start date: 2024-09-26
Primary completion: 2029-03-01
Enrollment: 380

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.